📖
Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis.
Corrales S, Pérez-Sánchez C, Cerdó T, Merlo C, Malvar-Fernández B, García S, Muñoz-Barrera L, Sanchez-Pareja I, Formanti L, Moreno-Caño E, Ortega-Castro R, Calvo J, Aranda-Varela C, Ladehesa L, Font P, Abalos-Aguilera MC, Ruiz-Vilchez D, Aguirre MÁ, Barbarroja N, Alarcon-Riquelme ME, Escudero-Contreras A, López-Pedrera C

Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Biomark Res.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis.
Author / Organization Corrales S, Pérez-Sánchez C, Cerdó T, Merlo C, Malvar-Fernández B, García S, Muñoz-Barrera L, Sanchez-Pareja I, Formanti L, Moreno-Caño E, Ortega-Castro R, Calvo J, Aranda-Varela C, Ladehesa L, Font P, Abalos-Aguilera MC, Ruiz-Vilchez D, Aguirre MÁ, Barbarroja N, Alarcon-Riquelme ME, Escudero-Contreras A, López-Pedrera C
Subject & Discipline Biomark Res
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-62519
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »